Effect of Efruxifermin on Digital Pathology Fibrosis Measures & Markers of Portal Hypertension in Compensated Cirrhosis Due to Mash

• Leveraging digital pathology fibrosis measures to generate more detailed assessments of tissue-level changes, improving evaluation of therapeutic impact and supporting more informed development decisions
• Evaluating markers of portal hypertension alongside fibrosis endpoints to provide a broader understanding of disease progression, enabling enhanced patient characterization and improving clinical trial interpretation
• Integrating innovative measures of advanced liver disease into therapeutic assessment strategies to strengthen efficacy evaluation, supporting development planning and accelerating progress toward meaningful patient outcomes

Speakers:

Susana Rios

International Medical Director

Novo Nordisk